Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

5 source entries across 5 studies. This list may not include all unresolved or historical entries.

Success Metrics

Active Trials
0(0%)

Phase Distribution

Phase 1
3
60%
Phase 2
1
20%
Phase 3
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Other(5)

Detailed Status

unknown4
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)

Trials by Status

suspended120%
unknown480%

Recent Activity

0 active trials
Showing 5 of 5
unknownphase_1

Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors

NCT03792958
suspendedphase_1

CM082 in Patients With Myopic Choroidal Neovascularization (CNV)

NCT04222842
unknownphase_3

CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

NCT03095040
unknownphase_2

Safety and Tolerability of Oral CM082 in Patients With wAMD

NCT03710863
unknownphase_1

Study of the Combination of CM082 With Everolimus in Patients With mRCC

NCT02577458

Clinical Trials (5)

Showing 5 of 5 trials
NCT03792958Phase 1

Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors

Unknown
NCT04222842Phase 1

CM082 in Patients With Myopic Choroidal Neovascularization (CNV)

Suspended
NCT03095040Phase 3

CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

Unknown
NCT03710863Phase 2

Safety and Tolerability of Oral CM082 in Patients With wAMD

Unknown
NCT02577458Phase 1

Study of the Combination of CM082 With Everolimus in Patients With mRCC

Unknown

All 5 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
5